Rx Surveillance User Fee Proposal Is Premature; PhRMA Responds To JAMA

Discussion of ways to fund expanded post-marketing surveillance activities by FDA should await a clear assessment of the extent of the problem, the Pharmaceutical Research & Manufacturers of America said in response to a May 20 Journal of the American Medical Association article entitled "Time To Take Action on Drug Safety."